Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease - Drug Lung Deposition In COPD

Imperial College London0 个研究点目标入组 65 人开始时间: 2012年3月29日最近更新: 2019年6月30日

试验速览

暂无简介。

•COPD patients, either male or female, over the age of 40 with a clincal diagnosis of COPD with airflow obstruction (FEV1/FVC<0.7) and post-bronchodilator FEV1>50% predicted, gas trapping (on lung volume testing), and decreased carbon monoxide transfer factor.
•Healthy subjects will be non-smokers (or ex-smokers stopped 5 years ago), will have no respiratory disease, normal spirometry and be age-matched to the COPD patients.
•Asthmatic subjects, either male or female, over the age of 18 with a clincal diagnosis of Asthma with airflow obstruction (FEV1/FVC<0.7).
•Capable of giving informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 43
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•1) Oral corticosteroids taken within last month.
•2)Current involvement (or involvement in the last 4 weeks)in clinical trials assessing investigational medicinal products.
•3)Previous adverse reaction to short or long acting ß2 agonist.
•4) Any subject with a contraindication to taking inhaled beta-2 adrenoceptor agonists (especially salbutamol) as listed in the British National Formulary will not be entered into this study.
•5) Those who have experienced an acute respiratory exacerbation requiring emergency room treatment and/ or hospitalisation within four weeks of visit 1 (screening visit).
•6) Pregnant or breast-feeding women.
•7) Subjects unable to give Informed Consent.

发起方